Cidara Therapeutics' possibilities are rising with Merck!

Cidara Therapeutics, Inc. (NASDAQ:CDTX) attracted investor interest last Friday. The company's stock price surged to nearly a ten-year high following the news that it is in the process of being acquired by the major pharmaceutical company Merck for $9.2 billion.

The stock reached a high of $218.85 during intraday trading, closing the day at $217.71, representing a gain of %105.41. This surge is indicative of the intense interest from investors in the company.

In its official agreement with Merck, Cidara Therapeutics announced that its shares will be purchased at a price of $221.50. The acquisition is expected to be completed in the first quarter of 2026.

Additionally, Cidara Therapeutics received a fast-track designation from the Food and Drug Administration for its drug candidate CD388, which aims to prevent influenza in individuals at high risk. Currently, CD388 is under evaluation in Phase 3 trials among adult and adolescent participants at high risk of influenza complications.

While we assess CDTX's potential as an investment opportunity, we believe that some artificial intelligence stocks may have a higher likelihood of providing better returns and carry less risk. If you are looking for an extremely cheap AI stock that significantly benefits from Trump’s tax policies and onshoring, we recommend checking out our best short-term AI stock report.